Testing Topical Infliximab Eye Drops After Cornea Transplant Surgery
Tests infliximab eye drops to see if they are safe after corneal transplant surgery.
Plain-language title generated from the registry record
Registry title: Topical Infliximab in Eyes With Penetrating Keratoplasty
Key facts
- Where
- Montreal, CanadaSee the site
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT05180994, who can take part
Where in Canada
- Centre Hospitalier de l'Université de MontréalMontreal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre hospitalier de l'Université de Montréal (CHUM)
- Trial code
- NCT05180994
- Record updated
- 27 April 2026
- Original description
Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.Read full original descriptionShow less
Topical Infliximab in Eyes With Penetrating Keratoplasty
Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.
Inclusion: Age between 18 and 80 years; First corneal transplant surgery; Capable of providing informed consent; Capable of administering eye medication or access to a caregiver able and willing to administer the eye medication for the patient.
Exclusion: Past corneal transplant (any technique); Current or anterior use of anti-TNF-α medication or other anti-inflammatory biologics; Active ocular infection; Advanced glaucoma or macular disease; Active or latent systemic infection (tuberculosis, histoplasmosis, coccidioidomycosis, cytomegalovirus, pneumocystis, aspergillosis or hepatitis B); Malignancy diagnosed in the past 5 years (any kind); Demyelinating disease; History or current diabetes mellitus (controlled or uncontrolled) or heart failure (New York Heart Association class III or IV); Allergy to infliximab or to a compound of its topical formulation; Significant anomaly of complete blood count or hepatic enzymes; Pregnancy or breastfeeding.